ABVC BioPharmaABVC +6.25%17 EBIT per Share is $-0.40 as of Mar. 2026. GuruFocus rates ABVC with a GF Score™ of 17/100 and a GF Value™ of $0.87 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,184 Biotechnology companies, ABVC BioPharma ranks better than 89.86% on this metric.
ABVC BioPharma's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.06.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.40.
During the past 3 years, the average EBIT per Share Growth Rate was 57.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 44.90% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 10.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for ABVC BioPharma's EBIT per Share or its related term are showing as below:
ABVC'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -56.9 Med: 38.5 Max: 91.4
Current: 57.9
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of ABVC BioPharma was 91.40% per year. The lowest was -56.90% per year. And the median was 38.50% per year.
ABVC's 3-Year EBIT Growth Rate is ranked better than 89.86% of 1184
companies
in the Biotechnology industry
Industry Median: 15.45
vs ABVC: 57.90
ABVC BioPharma's EBIT for the
three
months ended in Mar. 2026 was $-1.64 Mil.
ABVC BioPharma (NAS:ABVC) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
ABVC BioPharma EBIT per Share Related Terms
ABVC BioPharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for ABVC BioPharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABVC BioPharma (ABVC) has a EBIT per Share of $-0.40 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ABVC BioPharma and its competitors. According to the industry distribution chart, ABVC BioPharma ranks #120 out of 1184 companies in the Biotechnology industry, placing it in the top 10.1%.
Is ABVC BioPharma's EBIT per Share too high?
ABVC BioPharma's current EBIT per Share is $-0.40. Based on the distribution chart, ABVC BioPharma ranks #120 out of 1184 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ABVC BioPharma has a GF Score™ of 17/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ABVC BioPharma's EBIT per Share compare to GRDX and INMB?
According to the Biotechnology industry distribution chart, ABVC BioPharma ranks #120 out of 1184 companies for EBIT per Share. This places ABVC BioPharma in the top 10% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.45, based on 1,184 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ABVC BioPharma and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABVC BioPharma's current EBIT per Share is $-0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABVC BioPharma stock overvalued right now?
Based on GuruFocus' analysis, ABVC BioPharma (ABVC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $1.53 — trading 75.9% above its estimated fair value. The current EBIT per Share is $-0.40. ABVC BioPharma's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For ABVC BioPharma (ABVC), the current EBIT per Share is $-0.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABVC BioPharma (ABVC) Overvalued in 2026?
Based on GuruFocus' analysis, ABVC BioPharma stock appears to be overvalued.
The current stock price of $1.53 is trading 75.9% above its estimated GF Value™ of $0.87.
GuruFocus considers ABVC BioPharma to be Significantly Overvalued.
Key valuation signals for ABVC:
EBIT per Share: $-0.40
GF Value™: $0.87 vs. price of $1.53 (75.9% above fair value)
No single metric tells the full story. See the ABVC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
17GF Score
Get the complete analysis for ABVC
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABVC has been successfully added to your 
